SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Intarcia Therapeutics, Inc. to Present Analysis of Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD